44results about How to "Specific targeting" patented technology

The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs. Thereto, the compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to glutathione-based ligands that facilitate the specific binding to and internalization by these glutathione transporters.

A method of manufacturing at least one customized MIP unit including: (a) providing at least one MIP unit having a surface including at least one target binding site configured to resemble a target molecule and surface-bound chargeable groups; (b) contacting the MIP unit(s) from the step (a) with at least one template molecule in a first solvent allowing the template molecule(s) to bind to the MIP unit(s); (c) passivating the surface-bound chargeable groups on the MIP unit(s) by adding a passivating agent; and (d) removing the template molecule(s) by washing in a second solvent, wherein the passivating agent binds to the surface of the unit(s) through bonds which remain stable upon washing in the second solvent.

The invention provides an active targeting type amphipathic polypeptide nano-drug carrier and preparation and application thereof, and belongs to the technical field of biological medicines. According to an amphipathic polypeptide, an alkyl chain serves as the hydrophobic end, a polypeptide chain with active targeting functional and side chain modification fluorescent functional molecules serves as the hydrophilic end, and an anti-tumor drug is wrapped in a hydrophobic cavity of a micelle formed by self-assembling the amphipathic polypeptide. The nano-carrier can actively target tumor cells and enter the tumor cells through receptor-mediated endocytosis, the amphipathic polypeptide and phospholipid molecules have strong interaction, and the phagocytosis of a nano-drug by tumor cells is promoted. In the process, tracing can be conducted through fluorescent imaging of fluorescent functional molecules modified on the polypeptide chain, and the tumor imaging aim is realized. Finally, the anti-tumor drug is slowly released to kill tumor cells and restrain the growth of tumors. The amphipathic polypeptide nano-carrier is free of toxin, high in biocompatibility and remarkable in anti-tumor efficiency, and the tumor diagnosis and treatment can be integrated.

An antigen derived from an intracellular pathogenic micro-organism characterized in that it comprises at least on peptidic fragment which essentially consists of the concatenation of sequences of at least two extracellular adjacent areas in the native structure of a membrane protein of type III of said intracellular pathogenic micro-organism, derived conformational antibodies and the application hereof.

Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and / or diagnostic agents, for use in research and medical applications.

The present invention discloses a novel anti-crop-epiphyte polypeptide and a preparation method thereof. A recombined anti-crop-epiphyte polypeptide is formed by linking gene which codes white candida pheromone and the gene which codes colicin. Compared with the prior anti-crop-epiphyte medicine, the novel anti-crop-epiphyte polypeptide of the present invention has the advantages that the novel anti-crop-epiphyte polypeptide directly forms ionic passage at epiphytic cell membrane to kill the epiphyte, so the killing efficiency is thousands times stronger than the prior anti-crop-epiphyte medicine; the epiphyte can hardly amend the geometrical damage at the cell membrane caused by the polypeptide by the mutation-expression form, so the polypeptide can not induce the epiphyte producing the traditional drug resistance; the polypeptide is a biological preparation and has target killing towards the epiphyte, so the novel anti-crop-epiphyte polypeptide does not have the toxic and side effects of the prior anti-crop-epiphyte medicine.

The invention belongs to the field of biological medicinal preparation and relates to a preparation technology and an application of a natural recombinant nanostructured lipid carrier. The specifically-refereed nanoparticle is natural recombinant lipoprotein drug-loaded nanoparticle and is prepared by in vitro recombination of an apolipoprotein mixture and lipid which are obtained by extraction and purification of a blood plasma ingredient IV and a medicament. The recombination process is realized by a film dispersion method, an emulsification-evaporation method or an emulsification-evaporation improved method. The technical problem to be solved in the invention is the extraction and purification method of apolipoprotein and lipid mixture and the preparation technology of the natural recombinant lipoprotein drug-loaded nanoparticle. Preparation conditions are mild, and costs are low. The natural recombinant lipoprotein nanoparticle provided by the invention has remarkable advantages of spheroidic structure, high bionic performance, high penetrability, efficient carrying performance, tumor targeting and the like. The invention provides property evaluation and application of the above natural recombinant lipoprotein nanoparticle. Normal saline, or a phosphate buffer or 5% glucose solution is added to dissolve the nanoparticle, and the dissolved nanoparticle can be used to treat diseases in a mode of intravenous injection, intramuscular injection, oral medication or cutaneous penetration. The technology provided by the invention is simple and low-cost and is easy for industrial production.

The invention relates to a hyaluronic acid-modified amide hectorite nanoparticle and a preparation and an application of the hyaluronic acid modified hectorite amide nanoparticle. The hyaluronic acid modified hectorite amide nanoparticle is (3-amino propyl) ethoxydimethylsilane modified hectorite; and the mass fraction of the hyaluronic acid in the nanoparticle is 17.17%-19.09%. The preparation method comprises the following steps: modifying a hectorite surface with (3-amino propyl) ethoxydimethylsilane on to obtain hectorite amide; and through covalent action of amino and carboxyl, grafting the hectorite amide surface with hyaluronic acid, thus obtaining the hyaluronic acid modified hectorite amide nanoparticle. The stability and the biocompatibility of the nanoparticle are improved; meanwhile, the hyaluronic acid-modified hectorite amide nanoparticle has specific targeting action on cancer cells with high expression for a CD44 receptor, and can be applied to targeted delivery of anti-cancer drugs; and the hyaluronic acid-modified hectorite amide nanoparticle is simple in preparation method, mild in reaction condition and easy to operate, and has an industrial implementation prospect.

The invention relates to a fibronectin EDB subtype specific targeting short peptide A16 with an amino acid sequence of ATYRLFQGVEVV. The targeting short peptide A16 can specific recognize EDB-FN protein expressed by tumor cells, has high affinity to EDB-FN and is capable of carrying functional molecules with diagnosis or therapeutic activity to tumor cells to perform diagnosis or treatment effect.

Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.

The hHscFv gene sequences encode the plants. The synthetic DNA includes: the nucleic acid sequence which is 70% same to the 51-812bp nucleic acids of the SEQ IDNO.1 encodes the multi peptides with the hHscFv activity. The sequence encodes the multi peptides with the amino acid sequence of the SEQ ID NO.2. The peptides have the important value for curing the hepatocellular carcinoma.

The invention discloses an active targeting type amphiphilic polypeptide composite nano-micelle prodrug as well as preparation and application thereof, and belongs to the technical field of biological medicines. The composite nano-micelle prodrug is obtained by co-assembling a first polypeptide with negative charges and a second polypeptide with positive charges through electrostatic interaction and hydrophilic and hydrophobic effects; the first polypeptide is Lys-AAm-Gly-Arg-Gly-Asp-Ser, wherein AA is aspartic acid or glutamic acid, and m is 1, 2, 3 or 4; the second polypeptide is Cys-BBn, wherein BB is lysine, arginine or histidine, and n is 1, 2, 3 or 4; amino at a N end of the first polypeptide is connected with a hydrophobic alkyl chain, and amino at a lysine side chain of the first polypeptide is connected with a fluorescent molecule; cysteine in the second polypeptide is covalently linked with an anti-tumor drug through sulfydryl. The nano-composite micelle can be actively targeted to tumor cells, and is disassembled after responding to a tumor slightly acidic environment to form a small-size micelle with a size of 20-30 nm, so that deep delivery of the polypeptide anti-tumor prodrug at a tumor part is facilitated.

Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and / or diagnostic agents, for use in research and medical applications.

The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3′,5 ‘-monophosphate analogues as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.

The invention discloses a biomimetic multifunctional lipoprotein nanoparticle modified by biological peptide and a preparation method and application thereof, the multifunctional biomimetic lipoprotein nanoparticle is composed of a biomimetic lipoprotein nano-carrier shell modified by biological peptide and a nano-form drug core, and the carrier shell is composed of apolipoprotein bionic peptide, biological peptide and natural phospholipid substitute. The preparation method comprises a film dispersion method and an emulsification evaporation method. The preparation method disclosed by the invention is simple and mild in condition and low in cost, and the prepared biological peptide modified biomimetic multifunctional lipoprotein nanoparticle has the advantages of high drug loading capacity, high biomimetic property, strong penetrability, biological safety, lesion site targeting property, drug loading mode diversity and the like. A nano-drug delivery platform can realize 'diagnosis and treatment integration' and 'multi-mode combined treatment', and can realize timely diagnosis and efficient treatment of complex progressive diseases such as tumors, neurodegenerative diseases and the like.

The present invention belongs to the field of genetic engineering, and particularly relates to a genetically engineered dual-targeting chimeric antigen receptor. The present invention provides a genetically engineered dual-targeting chimeric antigen receptor and a host cell thereof in response to up-regulated expression of PD-L1 in tumor cells and immune cells after these cells are exposed to malignant serosal cavity effusion. The dual-targeting chimeric antigen receptor provided by the present invention competitively binds to PD-L1 to transform an inhibition signal of PD-L1 into an activation signal and to enhance the killing activity of T cells; meanwhile, 4-1BB introduced downstream thereof can promote proliferation and survival of T cells. In addition, the present invention also discloses a host cell expressing the above dual-targeting antigen receptor and a use thereof in preventing or treating solid tumors.

The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3′, 5′-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.

The invention provides uric acid-lowering molecules and a screening method and application of the uric acid-lowering molecules, wherein the amino acid sequence of the uric acid-lowering molecules is as shown in SEQ ID NO. 1; according to the invention, a random mutation library is constructed by using a phage display technology, and uric acid target molecules are constructed, affinity adsorption principles are used for screening the library, and the construction, screening and identification methods and steps are optimized to obtain the uric acid-lowering molecules for preparing a uric acid-lowering medicine, and the molecules are excellent in uric acid-lowering function, simple and high-efficient in screening method and worthy of being popularized and applied, thereby having broad application prospects and great market values.

The invention provides a macrophage-based living cell drug-loading system, which comprises a living cell and a drug-loading yeast bionic micromotor located in the living cell, the living cell is a macrophage, the drug-loading yeast bionic micromotor comprises a yeast cell wall, and the yeast cell wall is connected with the drug-loading yeast bionic micromotor. The glucose oxidase and the catalase are semi-modified on the yeast cell wall. According to the in-vivo self-assembled living cell medicine, after entering a human body through the medicine-carrying yeast bionic micromotor, the medicine actively penetrates through the intestinal wall, enters the lymphatic system in the intestine and is endocytosed by macrophages in the lymphatic system, so that the macrophage living cell medicine is self-assembled in vivo, and the medicine can be conveyed in a targeted manner.

Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and / or diagnostic agents, for use in research and medical applications.

The invention discloses a multi-response core-shell structure nanogel, and a preparation method and application thereof, and belongs to the technical field of gel preparation. The method specifically comprises the following steps: 1, preparing a nanogel aqueous solution by a reflux precipitation polymerization method; 2, coating the outer surface of the nanogel core with chitosan to obtain chitosan-coated nanogel; and 3, coating the outer surface of chitosan with a hyaluronic acid shell layer to obtain the core-shell mechanism nanogel. The nanogel core is coated with the chitosan and the hyaluronic acid, the nanogel with a core-shell structure is prepared, and the obtained nanogel has temperature / pH / reduction multiple stimulation responsiveness. The coated hyaluronic acid shell layer can be specifically combined with a CD44 receptor on the surface of cancer cells, so that the nanogel can specifically target tumor cells.

The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV / AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and / or decreases the number of monocytes and / or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.

The invention discloses a fusion protein of a complement receptor 2 mutant and a complement inhibitor CD 59 and application thereof to preparing autoimmune disease treating drugs. The complement receptor 2 mutant is a molecular modified body obtained through computer modelling and amino acid replacement and is higher in ligand binding and dissociation rate and ligand binding force compared with wild sequences. Biological distribution test shows that the fusion protein can be highly concentrated at arthritic parts after entering mouse models with rheumatoid arthritis and achieve significant anti-adhesion / anti-inflammatory targeted inhibition effects; when applied to treating MRL / lpr (Murphy Roths large / lymphoproliferation) mice with systemic lupus erythematosus, the fusion protein can significantly improve the survival rate of the mice, and symptoms of the mice of a treatment group such as proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent glomerulonephritis / necrosis can be significantly improved.

This invention relates to a hEscFv gene sequence that composes by the plant preference codon, which belongs to the gene project field. This invention includes: the code designed by the plant preference codon has the nucleotides sequence which has the biology activity hEscFv polypeptides, and the nucleotides sequence has at least 70% same fountain with the 51-800 nucleotides in the SEQ ID NO. 1; or they can cross under the middle tension condition. The polypeptides are expressed or produced in the eukaryotic, the character of which is that they have the amino acid sequence showed in the SEQ ID NO. 2 of the list, and the eukaryotic product has the target action to the vessel epidermal growth factor (EGF), and it is important for borderline tumour treatment.

The invention discloses a complement receptor 2 variant, a fusion protein of the complement receptor 2 variant and a complement inhibitor and application of the fusion protein in preparing a medicament for treating autoimmune diseases. The complement receptor 2 variant is a molecular modified body obtained after computer modeling and amino acid replacement, has higher ligand binding and dissociation rate and better ligand binding force than a wild sequence of the complement receptor 2 variant. The biological distribution experiment proves that the fusion protein provided by the invention can rapidly and highly aggregate at an arthritis part after entering a rheumatoid arthritis mouse model, and has a remarkable anti-adhesion / anti-inflammation targeted inhibition effect. In the treatment ofMRL / lpr lupus erythematosus mice, the fusion protein can obviously improve the survival rate of the mice, and symptoms such as proteinuria, glomerular integral, interstitial inflammation, vasculitis,crescent / necrosis and the like of the mice in the treatment group are obviously improved.

The invention provides a gene, recombinant plasmid and polypeptide for an anti-tumor binary polypeptide. The gene of the recombinant anti-tumor binary polypeptide is obtained by connecting in an operable way the gene of a coding antibody simulator with a recombinant bacillus anthraci protein antigen gene. The recombinant plasmid of the invention is formed by inserting the gene of the coding antibody simulator by double-chain oligomeric nucleotide directed mutagenesis method into the recombinant bacillus anthraci protein antigen gene. The obtained recombinant plasmid is infected into engineering bacillus coli BL-21 to get engineering bacillus coli cell of anti-tumor binary polypeptide; the anti-tumor binary polypeptide can be obtained by expanding the bacillus coli, settling in centrifugalway the bacillus coli body, crushing in altrasonic way, settling and crushing bacillus coli body by hi-speed centrifuging and treating the upper clean solution. The anti-tumor binary polypeptide is of special targeting characteristic, higher efficiency in killing special physical tumor than prior anti-tumor medicine, and will not attack normal cells, and has much lower toxicity and poor-reactionthan prior anti-tumor medicine.